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Introduction
Despite major advances in medical and surgical treatment of
heart failure, heart transplantation is still the elective treat-
ment for patients refractory to other medical therapies or
conventional cardiac procedures.1 Due to improved results,
the criteria for selection of candidates for transplantation
have been gradually extended and the age has been one of the
criteriamore exposed.2However, the upper age limit remains
poorly deﬁned, partly due to the high demand for transplan-
tation and the scarcity of organs. Still, advanced age has
traditionally been viewed as a contraindication for heart
transplantation, despite the improved outcomes recently
reported.3
Older candidates often have multiple cardiovascular risk
factors and deﬁcient physical and psychological conditions
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Abstract Background Patients older than 65 years have traditionally not been considered
candidates for heart transplantation. However, recent studies have shown similar
survival. We evaluated immediate and medium-term results in patients older than
65 years compared with younger patients.
Methods From November 2003 to December 2013, 258 patients underwent trans-
plantation. Children and patients with other organ transplantations were excluded from
this study. Recipients were divided into two groups: 45 patients (18%) aged 65 years and
older (Group A) and 203 patients (81%) younger than 65 years (Group B).
Results Patients differed in age (67.0  2.2 vs. 51.5  9.7 years), but gender (male
77.8 vs. 77.3%; p ¼ 0.949) was similar. Patients in Group A had more cardiovascular risk
factors and ischemic cardiomyopathy (60 vs. 33.5%; p < 0.001). Donors to Group A
were older (38.5  11.3 vs. 34.0  11.0 years; p ¼ 0.014). Hospital mortality was 0 vs.
5.9% (p ¼ 0.095) and 1- and 5-year survival were 88.8  4.7 versus 86.8  2.4% and
81.5  5.9 versus 77.2  3.2%, respectively. Mean follow-up was 3.8  2.7 versus
4.5  3.1 years. Incidence of cellular/humoral rejection was similar, but incidence of
cardiac allograft vasculopathy was higher (15.6 vs. 7.4%; p ¼ 0.081). Incidence of
diabetes de novo was similar (p ¼ 0.632), but older patients hadmore serious infections
in the 1st year (p ¼ 0.018).
Conclusion Heart transplantation in selected older patients can be performed with
survival similar to younger patients, hence should not be restricted arbitrarily. Incidence
of infections, graft vascular disease, and malignancies can be reduced with a more
personalized approach to immunosuppression. Allocation of donors to these patients
does not appear to reduce the possibility of transplanting younger patients.
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and it is known that the immediate results of transplantation
are very sensitive not only to the quality of the donor organ
but also to the clinical status of the candidate to transplanta-
tion. Adequate selection of recipients is essential to the
success of a transplantation program.
In this article, we analyzed our own experience and
compared the early and late results of cardiac transplanta-
tion in two groups of patients, younger and older than
65 years.
Methods
Deﬁnition, Origin, and Collection of Data
In the period from November 2003 to December 2013, 258
patients were consecutively submitted to heart transplanta-
tion at this center. Exclusion criteria for this study included
patients previously transplanted with other organs (n ¼ 2)
and patients younger than 18 years (n ¼ 8). In this way, the
study population comprised 248 patients, of whom 72 (29%)
were in the intensive care unit, under inotropic support and/
or mechanical assistance, while 176 (71%) were awaiting
transplantation at home.
The data for this patient population were obtained from a
national database speciﬁcally designed for the prospective
registration (online platform) of data of recipient, donor,
surgery, immunosuppression protocol, and follow-up of pa-
tients undergoing cardiac transplantation.
All surviving patients were followed by regular consulta-
tion at the surgical center by a dedicated medical/surgical
team, for 1 to 10 years, and none was lost to follow-up. The
mean follow-up period in this study was 4.4  3.1 years
(1,091 patient-years).
Recipients and Donors
►Table 1 shows the preoperative data of the recipients of the
two groups and respective donors, as well as the results of the
comparative analysis.When comparedwith the population of
Group B, patients in Group A had a higher rate of cardiovas-
cular risk factors, such as hypertension (53.3 vs. 35.5%;
p ¼ 0.026), dyslipidemia (71.1 vs. 43.3%; p ¼ 0.001), prior
cardiac surgery (44.4 vs. 26.1%; p ¼ 0.015), prior coronary
artery bypass grafting (CABG) (24.4 vs. 12.3%; p ¼ 0.037),
ischemic cardiomyopathy (60 vs. 33.5%; p ¼ 0.001), and
carotid disease (57.8 vs. 34.5%; p ¼ 0.004). They also had
decreased glomerular ﬁltration rate (49.2  15.4 vs.
63  23.2 mL/min; p < 0.001), and higher serum creatinine
(1.6  0.8 vs. 1.4  0.5mg/dL; p ¼ 0.099). Finally, therewere
fewer patients in high urgency for transplantation (equivalent
to United Network for Organ Sharing (UNOS) status 1A and 1B)
in Group A than in Group B (22.2 and 29.5%, respectively;
p ¼ 0.174), and the timeon thewaiting list was 48.8  50.0 vs.
42.3  44.6 days, respectively (p ¼ 0.384).
There were no major differences in any of the variables
between the two groups, with regard to donors. Male donors
were most common (66.7 vs. 76.8%) and the cause of death
was mostly traumatic (51.1 vs. 57.6%). However, there was a
signiﬁcant number of older donors for patients in group A
(38.5  11.3 vs. 34.0  11.0% years; p ¼ 0.014), who also
had a tendency for prolonged inotropic (8.9 vs. 3%;
p ¼ 0.067) or ventilator support (20 vs.10.3%; p ¼ 0.072).
In total, there were 53 donors older than 45 years (21.4%), 16
in group A (35.6%) and 37 in group B (18.2%; p ¼ 0.014). The
distribution of donor age versus recipient age is shown
in ►Fig. 1.
Due to the fact that our region counts with a high donation
rate (37.8 donors/million population), 41% of the donors were
local and 59% distant (mean ¼ 168  78 km).
Surgical Technique
All transplantations were performed using the bicaval meth-
od, under cardiopulmonary bypass (CPB) and moderate sys-
temic hypothermia (28°C). To decrease ischemic times,
priority is given to the left side heart anastomoses after which
the aortic cross-clamp is removed and the anastomoses of the
right side are done under perfusion. Typical ischemic time
was 40 to 45minutes for local donation and 90 to 120minutes
for distant harvesting. All patients received an infusion of
dobutamine (5 µg/kg/min) after all the anastomoses were
completed, for its chronotropic effect. Need for further ino-
tropic support or posttransplantation mechanical assistance
was determined after a period of adequate reperfusion and
this decision was based on intraoperative direct visualization
of the heart, hemodynamic signs, and transesophageal
echocardiogram.
Of notice, as another method to expand the numbers of
donors, and based on the large experience of the center with
this procedure, concomitant mitral valvuloplasty was per-
formed in 12 donor hearts previously known to have moder-
ate mitral valve disease, 4 in Group A and 8 in Group B. On
most occasions, this was done in the form of a suture
posterior annuloplasty, but other procedures were
performed.4
Immunosuppression Therapy and Rejection
Monitoring
Routine induction therapy consisted of mycophenolate mo-
fetil (1 g oral), methylprednisolone sodium succinate
(500 mg i.v.) and basiliximab (20 mg i.v.) administered pre-
and during transplantation. After transplantation, patients
entered a protocol consisting of a calcineurin inhibitor (most-
ly cyclosporin, dose-adjusted to blood levels assessed by
monoclonal ﬂuorescence polarization immunoassay), myco-
phenolate mofetil (1 g twice daily), and steroids (125 mg of
methylprednisolone intravenously every 8 hours for three
doses postoperatively, followed by prednisone, 0.8mg/kg/day
during the 1st week and then tapered off in the subsequent
4 weeks to 0.2 mg/kg/day).
Right ventricular endomyocardial biopsies were per-
formed by a routine protocol or when it was considered to
be clinically necessary, and acute cardiac rejection was diag-
nosed and treated if  2R according to the International
Society for Heart and Lung Transplantation (ISHLT)
classiﬁcation.4
Coronary angiograms were performed at yearly intervals.
Cardiac allograft vasculopathy followed the deﬁnitions pro-
posed by the ISHLT.5,6
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Statistical Analysis
Continuous variables are presented as mean  standard de-
viation and evaluated using the independent Student t-test
for normally distributed continuous variables and Mann–
Whitney U test for nonnormally distributed continuous
variables. Normality was accessed by the Kolmogorov–Smir-
nov and Shapiro–Wilk tests. Categorical variables are re-
ported as frequency and percentage, and compared using
the chi-square test or the Fisher exact test when appropriate.
Survival and event-free survival were calculated by the
Kaplan–Meier method and comparison between groups ob-
tained by log-rank test. Statistical signiﬁcance was deﬁned as
p value < 0.05 (two-tailed). Data were analyzed using the
IBM Corp. program (released 2011; IBM SPSS Statistics for Fig. 1 Adult heart transplantation: donor and recipient age.
Table 1 Characterization of the recipient and donor populations
Recipient group A B p
N 45 203
Age (y, mean  SD); range (minimum–maximum) 67.0  2.2 (65–72) 51.5  9.7 (20–64) < 0.001
Gender (male) 35 (77.8%) 157 (77.3%) 0.949
Follow-up (y) 3.8  2.7 4.5  3.1 0.146
Wait-list time (d) 48.8  50.0 42.3  44.6 0.384
BMI mean (kg/m2) 23.8  3.0 23.8  3.4 0.996
Diabetes 15 (33.3%) 56 (27.6%) 0.440
Hypertension 24 (53.3%) 72 (35.5%) 0.026
Dyslipidemia 32 (71.1%) 88 (43.3%) 0.001
Prior cardiac surgery 20 (44.4%) 53 (26.1%) 0.015
Ischemic cardiomyopathy 27 (60.0%) 68 (33.5%) 0.001
Dilated cardiomyopathy 9 (20.0%) 66 (32.5%) 0.098
Peripheral vascular disease 19 (42.2%) 64 (31.5%) 0.169
Cardiac index (L/min/m2) 1.9  0.4 2.0  0.5 0.229
Transpulmonary gradient (mm Hg) 9.9  3.5 9.4  4.8 0.444
Pulmonary vascular resistance (WU) 3.6  2.8 3.3  2.1 0.399
VO2 max (mL/kg/min) 13.9  2.5 13.2  2.8 0.141
Glomerular ﬁltration rate (mL/min) 49.2  15.4 63.0  23.2 < 0.001
Creatinine level (mg/dL) 1.6  0.8 1.4  0.5 0.099
Urgency/emergency 10 (22.2%) 62 (30.6%) 0.174
Donor
Age (y) 38.5  11.3 34.0  11.0 0.014
Gender, male 30 (66.7%) 156 (76.8%) 0.154
Inotropic dependence > 1 wk 4 (8.9%) 6 (3.0%) 0.067
Ventilatory assistance > 1 wk 9 (20.0%) 21 (10.3%) 0.072
Donor female/recipient male 10 (22.2%) 33 (16.3%) 0.339
Death by cerebral vascular accident 15 (33.3%) 71 (34.8%) 0.933
Death by brain trauma 23 (51.1%) 117 (57.6%) 0.425
Local procurement 14 (31.0%) 88 (43.3%) 0.180
Distant procurement 31 (69.0%) 115 (56.7%) 0.180
Abbreviations: BMI, body mass index; SD, standard deviation. P values in bold are those considered signiﬁcant
Note: Univariate comparative analysis of preoperative data of Groups A and B.
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Windows, Version 20.0; IBM Corp., Armonk, New York,
United States).
Results
Surgery
The surgical data, as well as the results of the comparative
analysis of the two groups, are shown in ►Table 2. No
statistically signiﬁcant differences were observed relatively
to times of ischemia (96.3  35.2 vs. 88.8  36.4 minutes;
p ¼ 0.213), CPB (97.3  22.8 vs. 101.9  49.2 minutes;
p ¼ 0.543), and mechanical ventilation (17.1  8.9 vs.
20.9  26.4 hours; p ¼ 0.347). There were also no signiﬁcant
differences in the need for inotropic (17.8 vs. 12.8%;
p ¼ 0.381) or mechanical circulatory (6.7 vs. 4.9%;
p ¼ 0.636) support.
Therewas no hospital mortality in Group A and therewere
12 early deaths (5.9%) in Group B (p ¼ 0.095). The length of
hospital stay was similar in both groups (17.4  14.4 vs.
15.3  15.8 days; p ¼ 0.454).
After a mean follow-up of 4.4  3.1 years (1–10 years;
1,091 patient-years), the overall mortality did not show
signiﬁcant differences between the two groups of patients
(28.9vs. 22.7%; p ¼ 0.375) and the same goes for comparison
of in-hospital mortality and death at 6 months, 1 year, and
late follow-up between both groups (►Table 3). The most
frequent causes of death in both groups were infections
(11.1 vs. 5.9%; p ¼ 0.212) and peripheral vascular disease
(4.4 vs. 5.4%; p ¼ 0.791).
Overall survival up to 8 years after transplantation did not
differ between the older age group and the younger group, as
shown in the respective survival curves (►Fig. 2, p ¼ 0.289).
Survival rates at 1, 5, and 8 years were 88.8  4.7, 81.5  5.9,
and 52.3  12.7%, respectively, and median survival was
6.7  0.6 years for older patients; equivalent rates were
86.8  2.4, 77.2  3.2, and 72.0  3.9%, respectively, and
median survival was 7.9  0.3 years for the younger age
group.
Cellular and/or Humoral Rejection, and Graft Vascular
Disease
The data on acute cellular rejection, humoral rejection, and
vascular disease of the graft in Groups A and B are shown
in ►Table 4. One hundred and four patients (42%) had no
Table 3 Mortality and causes of death
Recipient group A B p
N 45 203
Hospital mortality 0 (0.0%) 12 (5.9%) 0.095
Total mortality 13 (28.9%) 46 (22.7%) 0.375
Mortality < 6 mo 5 (11.1%) 21 (10.3%) 0.879
Mortality < 1 y 5 (11.1%) 26 (12.8%) 0.756
Causes of death
Cardiac 1 (2.2%) 8 (3.9%) 0.577
Vascular 2 (4.4%) 11 (5.4%) 0.791
Malignant tumor 2 (4.4%) 6 (3.0%) 0.609
Neuropsychiatric 0 (0.0%) 4 (2.0%) 0.342
Infectious 5 (11.1%) 12 (5.9%) 0.212
Note: Univariate analysis of comparative data in Groups A and B.
Table 2 Peri- and postoperative data
Recipient group A B p
N 45 203
Total ischemic time (min) 96.3  35.2 88.8  36.4 0.213
CPB time mean (min) 97.3  22.8 101.9  49.2 0.543
Time to extubation (h) 17.1  8.9 20.9  26.4 0.347
Inotropic requirement 8 (17.8%) 26 (12.8%) 0.381
Mechanical assistance 3 (6.7%) 10 (4.9%) 0.636
Hemorrhage 5 (11.1%) 9 (4.4%) 0.079
Mitral valvuloplasty 4 (8.9%) 8 (3.9%) 0.162
Length of hospital stay (d) 17.4  14.4 15.3  15.8 0,454
Note: Univariate analysis of comparative data of Groups A and B.
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episodes of acute cellular rejection (grade 0R of the ISHLT).
The remaining patients (n ¼ 144, 58%) had at least one
episode of rejection, but it was only mild (1R), requiring no
treatment, in 99 of these. The comparative analysis of the two
groups showed no statistically signiﬁcant difference in any of
the cellular rejection grades. Forty-ﬁve patients (18.1%), 7
(15.5%) in Group A and 38 (18.7%) in Group B, had at least
one episode of cellular rejection grade  2R, the majority
(39 cases, 86.7%) occurring during the 1st year. No statistically
signiﬁcant difference (p ¼ 0.652) was observed in the sur-
vival free from cellular rejection grade  2R between Groups
A and B (►Fig. 3A).
Humoral rejection was diagnosed in six patients (2.4%),
with no signiﬁcant difference between the study groups
(p ¼ 0.924). Graft vascular disease (GVD) was diagnosed in
22 patients (8.8%), with some difference in the incidence
between the study groups (15.6 vs. 7.4%; p ¼ 0.081). Survival
free from GVD was signiﬁcantly different between the two
groups (p ¼ 0.001, ►Fig. 3B).
New Onset Diabetes and Severe Infections
The incidence of diabetes de novo in the 1st year after
transplantation was 13.3%, with no difference between the
two groups (11.1 vs. 13.8%; p ¼ 0.632).
The incidence of serious infections requiring hospitaliza-
tion and i.v. antibiotics during the 1st year posttransplanta-
tion was signiﬁcantly higher in Group A (28.9 vs. 14.3%;
p ¼ 0.018). In fact, the incidence of pneumonia in the ﬁrst
6 months was signiﬁcantly higher in Group A (37.8 vs. 22.7%;
p ¼ 0.035). Survival free from serious infections was signiﬁ-
cantly lower in Group A throughout follow-up (p ¼ 0.028), as
shown in ►Fig. 3C.
Renal Function after Transplantation
At the time of transplantation, patients in Group A showed a
tendency to a lower value of the glomerular ﬁltration rate
(GFR), as compared with Group B patients (49.2  15.4 vs.
63  23.2 mL/min; p < 0.001) and creatinine (1.6  0.8 vs.
1.4  0.5 mg/dL; p ¼ 0.099). At 1 month posttransplantation,
a tendency toward recoveryof the renal functionwas observed
in both groups, although this was not statistically signiﬁcant.
However, thiswas followed by progressive deterioration of the
GFR, so that from the 1st to the 6th months posttransplanta-
tionvalues dropped signiﬁcantly in both groups and continued
to decline in Group A (45.2  15.5 mL/min) and, although at a
slower pace, inGroupB (58.9  24.0mL/min) up to12months.
The progression of chronic renal failure to end-stage renal
disease required dialysis in four patients. Two of these under-
went kidney transplantation.
Malignancies
Older patients had an increased risk of development of malig-
nancies after transplantation (26.7 vs. 13.3%; p ¼ 0.026), clearly
demonstrated in the 5-year free survival of 67.7  9.1 and
87.0  3.0%, respectively (p ¼ 0.002) (►Fig. 3D).
Discussion
There is still some controversy and even reluctance to offer
cardiac transplantation to older patients, especially above
Fig. 2 Overall survival in Groups A and B.
Table 4 Data on rejection and other complications
Recipient group A B p
N 45 203
No rejection (0R) 17 (37.8%) 87 (42.9%) 0.532
Acute cellular rejection 2R 5 (11.1%) 31 (15.3%) 0.474
Acute cellular rejection 3R 2 (4.4%) 7 (3.4%) 0.746
Humoral rejection 1 (2.2%) 5 (2.5%) 0.924
Graft vascular disease 7 (15.6%) 15 (7.4%) 0.081
New onset diabetes 5 (11.1%) 28 (13.8%) 0.632
Cancer 12 (26.7%) 27 (13.3%) 0.026
Pneumonia  6 mo 17 (37.8%) 46 (22.7%) 0.035
Infections  12 mo 13 (28.9%) 29 (14.3%) 0.018
Note: Univariate analysis of comparative data in Groups A and B.
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70 years of age, resulting from consideration that they most
often have associated comorbidities that inﬂuence life expec-
tancy, thus signiﬁcantly reducing the potential beneﬁt of the
procedure.7 In addition, there is the presumption of greater
difﬁculties to withstand the rigors of surgery and associated
complications, notably those related to immunosuppression.8
This limitation is now being questioned, due to the satisfac-
tory results reported in septuagenarians.9 In fact, the advan-
ces in heart transplantation during the recent decades have
considerably changed the clinical practice and outcome in
most centers. Yet, the percentage of patients older than
65 years currently being transplanted is 17% in North Amer-
ica, and in Europe (Eurotransplant) is only 6.7%.10,11
The main argument against cardiac transplantation in old
people is their short life expectancy, to which one has to add
the scarcity of organs for transplantation. In choosing a donor
one is looking for the best result, hence patients with a higher
potential of functional recovery, low morbidity, and long
survival will naturally have priority. How canwe, then, justify
transplantation of an old person when the donors are scarce
for the young? Which should be the age limit to transplant?
These questions are being asked almost daily, as the popula-
tion older than 65 years now accounts for approximately 20%
of the total, and greater in some settings. In 2011, UNOS
highlighted the signiﬁcant increase in the percentage of
transplanted patients older than 65 years compared with
2001 (17 vs. 10.8%) and demonstrated a 5-year survival of 74%
for those undergoing heart transplantation in 2005 to 2006.10
On the contrary, when one extrapolates the results of the
older population (even octogenarians) submitted to conven-
tional cardiac surgery, we ﬁnd low rates of morbidity and
mortality and improved clinical, functional autonomy, and
quality of life.12,13 In both situations, the decisive factor is the
careful selection of the patient. Evidently, in this setting of
refractory chronic cardiac failure, often resulting in poor
physical and psychological condition, not every older patient
can be a candidate for transplantation.
In our experience, there was a natural and undeniably
selective inclusion process for older patients in the waiting
list for transplantation, which is difﬁcult to characterize and
quantify. Transplanted patients older than 65 years were
mostly male, with predominantly ischemic heart disease
(60%), a high incidence of carotid and peripheral vascular
disease (42 and 57%), diabetes (33%), hypertension and
Fig. 3 Survival free from complications related to immunosuppression in Groups A and B. (A) Cellular rejection grade  2R (ISHLT). (B) Graft
vascular disease. (C) Infection. (D) Malignancy. ISHLT, International Society for Heart and Lung Transplantation.
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dyslipidemia, and 44% of them had previous cardiac surgery
(CABG, 25%). As expected, the renal function was more
impaired in these patients than in the younger group. All of
these are known important risk factors of morbidity and
mortality after transplantation, thus signiﬁcantly limiting
beneﬁt. In the experience of Goldstein et al with heart
transplantation in septuagenarians, there was a similar inci-
dence of ischemic heart disease (59%), yet there were a
smaller number of diabetic patients (19%), fewer patients
with peripheral vascular disease (4.5%), and the serum creat-
inine levels were slightly lower.14
The priority and selection of the donors for these patients
is another topic of discussion. In our case, the typical donor
assigned to older patients (Group A) was older and 35.6% of
these donors were older than 45 years and had longer
mechanical ventilation or inotropic support, thus often con-
sidered as suboptimal. Yet, this has not had a negative impact
on perioperative and hospital mortality, although a higher
incidence of early transient graft dysfunction was apparent
(17.8 vs. 12.8%; p ¼ 0.381). In fact, there was no early
mortality in Group A, but mortality at the end of 1st year
was similar in the two groups.
However, the number of infectious episodes who required
hospitalization and intravenous antibiotic treatment during
the ﬁrst posttransplant year was higher in Group A (28.9 vs.
14.3%; p ¼ 0.018), a circumstance that may have had relevant
impact in the overallmortality. The greatest riskof developing
serious infections in this group of patients should alert us to
the need for taking more forceful prevention measures. Also,
relevant was the incidence of malignant pathology in Group
A, reﬂected by a signiﬁcant difference in free survival at
5 years (67.7  9.1 vs. 87.0  3.0%; p ¼ 0.002). Finally, a
higher incidence of GVD (15.6 vs. 7.4%) was observed in
Group A, with a trend toward statistical signiﬁcance
(p ¼ 0.081), a fact that is reinforced when we look at the
free-survival curve (73.4  9.4 vs. 93.6  2.2%, at 5 years;
p ¼ 0.010). This disease is a multifactorial entity, which is
more aggressive in individuals with risk factors or predicted
cardiovascular disease, more present in older patients.
By contrast, the incidence of acute cell rejection that
required treatment ( 2R) was similar in both groups
throughout the follow-up. This appears to be a common
occurrence inmany studies in this age group.15,16 The decline
in immune competence that occurs with aging is associated
with a progressive reduction in the generation of new T and B
lymphocytes, with the consequent loss of diversity and
functional competence.17 It establishes a dramatic reduction
in responsiveness as well as disruption of the function. Both
facts contribute to lower rejection rates but to the increased
incidence inmorbidity andmortality from infectious diseases
and cancer.18,19
The understanding of this immunosenescence thus re-
quires a different attitude in the handling of the immunosup-
pression in this age group. Therefore, it has been suggested by
others that the immunosuppression load be reduced so as to
minimize its side effects without increasing the risk of rejec-
tion, especially in the 1st year posttransplant, when it could
be expected to diminish the number of infectious episodes
and its impact on mortality. Similarly, it could also reduce the
incidence of malignancies and GVD.20 We were aware of this
phenomenon early in this experience and the results re-
ported herein may already incorporate the beneﬁts thereof.
Also analyzed in this study was the evolution of the renal
function, measured by the serum creatinine level and creati-
nine clearance, during the 1st year, as it would be at this time
that one would expect greater divergence. In both groups,
there was a stabilization or improvement of the renal func-
tion immediately after transplantation, but this was followed
bya gradual deterioration of the GFRover the 1st year, greater
in Group A (42.2  15.5 vs. 58.9  24.0 mL/min; p ¼ 0.002).
An eventual reduction of the immunosuppression doses may
also have an impact here.21,22
Despite these complications, the survival curve in the
medium term is similar in older and younger transplant
patients, although we appear to witness a decrease in the
long-term survival, which has to be naturally expected in this
population. Increased and differentiated care, not only in the
selection of candidates for transplantation but also in post-
operative care and follow-up (medium and long term), con-
ditions we can only ﬁnd in units with high volume and
experience, will almost certainly improve outcomes.23,24
A last comment, paradoxically, the simple existence of
these older candidates in the waiting list, parallel to better
donor procurement, appears to facilitate the use of better
donors in younger candidates, perhaps raising questions of
ethical order, although the use of marginal donors has been
demonstrated to have an acceptable outcome also in younger
individuals.25
Conclusion
The number of patients awaiting heart transplantation has
been increasing, unlike the supply of donors. This panorama
requires strengthening of the borders of donation and the
need to consider responsibly and pragmatically the allocation
of available organs. This situation becomes more complex
when there is an increase in the number of older patientswho
are potential candidates for transplantation. In our experi-
ence, the results obtained in older patients were similar to
those in younger recipients, at least in the medium-term
survival, but with signiﬁcantly higher rates of important
morbidity. The results could perhaps be improved by reduc-
ing the intensity of immunosuppression in this population.
The allocation of donors to this older group does not seem
to reduce the overall success of transplantation, but it is
difﬁcult to assess the impact on the younger population
awaiting transplantation. The key will be a more rigorous,
responsible, and pragmatic selection of both patients and
donors.
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Age Over 65: To Transplant or Not to Transplant?
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00000000
Orthotopic heart transplantation (OHT) is still the only cura-
tive treatment for patients with terminal heart failure.
However, widespread use of heart transplantation has been
increasingly limited by the growing discrepancy between the
number of patients on the waiting list and the number of
available organs. On the contrary, as population of people
older than 65 years is increasing these days, the prevalence of
heart failure is increasing, leading to more patients with
terminal heart failure. The recent article1 shows similar out-
comes in heart transplant recipients older than 65 years
compared with younger patients. Previous publications on
survival outcomes of OHT in older patients showed conﬂict-
ing results.2–10
Some large-cohort registry analyses—for example, the
International Society for Heart & Lung Transplantation
(ISHLT) registry—have identiﬁed older age as a risk factor
for both early and late mortality after OHT.2,3,6–8 In older
recipients, death from graft failure together with cardiac
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allograft vasculopathy and acute rejection becomes less
common, whereas death from nonlymphoma malignancy,
renal failure, organ failure, and infection increases.6 Other
single-institutional experiences have demonstrated that with
careful patient selection, OHT can be performed in elderly
patients with mortality and morbidity equivalent to younger
recipients as reported in other publications.1,5,9 Furthermore,
multicenter data have demonstrated acceptable long-term
outcomes in selected older recipients.10However, despite the
overall similar results in selected older transplant recipients
comparedwith younger patients, the conﬂict of transplanting
in older patients still remains.11 The waiting time and urgen-
cy for a patient on thewaiting list has risen over the last years.
The increasing organ shortage, which entails longer waiting
time and the fact that sicker patients are transplanted, is
considered to be an important factor for the declining results
over the last years. The criteria that account for the high-
urgency status are almost the same as the risk factors for
1-year mortality.6 As a consequence, the expected outcome
after transplantation has gained increasing attention both in
the transplant community and in the general public.12
In fact, next to the urgency of the transplantation
the chances of success are explicitly named as the second
important allocation principle in the German transplant law.
Recently, allocation based on urgency and outcome has
already been realized for lung transplantation by the intro-
duction of the lung allocation scores (LAS) in 2011. The initial
experiences with the LAS are promising; therefore, a cardiac
allocation score has currently been developed.13 The conse-
quence will be that a younger patient with a higher probabil-
ity of long-term survival will have a higher chance of getting a
transplant than a patient of advanced age, for example, older
than 65 years. Older recipients will not be excluded from
heart transplantation in general, but the rare organs will
primarily be allocated to younger patients. For older patients,
an “old-for-old” program could be introduced. Then, hearts
from younger donors would be reserved for younger recip-
ients with a higher probability of favorable long-term out-
come. Alternatively, older patients could receive a left
ventricular assist device, either as destination therapy or as
bridge-to-transplantation. A recent UNOS analysis demon-
strated that OHTrecipients aged 70 years and older whowere
bridged with ventricular assist device had outcomes equiva-
lent to patients younger than 70 years.3
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